COGT

26.8203.32%
AR

Andrew R. Robbins

President, CEO & Director

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was a Director at Turmeric Acquisition Corp. since October 2020 until December 2022. He has been an Independent Director at Harpoon Therapeutics, Inc. since March 2020. Mr. Robbins is credited with leading the highly successful U.S. launch of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in BRAF-mutant metastatic melanoma. Mr. Robbins is a medical oncologist with substantial experience in clinical practice, legislation, public policy and advocacy and for nearly a few decades, served in various executive leadership capacities for ASCO. Mr. Robbins served as the Chief Operating Officer of Array BioPharma Inc., since March 2015 until July 2019. In this role, Mr. Robbins was responsible for working with Array's research and development teams to refine its strategy, prioritizing portfolio investments and supporting corporate collaborations with Array's strategic partners. He served as Senior Vice President of Commercial Operations at Array BioPharma since July 23, 2012 until March 2, 2015. He has extensive commercial, development and strategic leadership expertise from a career in the pharmaceutical industry, with a specific focus on oncology/hematology products. From January 2007 to July 2012, he held management positions at Hospira, Inc., including as Vice President of Corporate Development. At Hospira, Inc., he served as General Manager/Vice President of the U.S. Alternate Site business unit, focused on the sales of pharmaceuticals and medical devices to outpatient oncology, surgery, pain and dialysis customers. Mr. Robbins served as Vice President of Corporate Development and was responsible for global branded pharmaceutical marketing and business development, research and development portfolio prioritization, global strategy and corporate venture investing. During his tenure, he designed and executed a strategy to build a late-stage hematology/oncology and acute pain pipeline via licensing and acquisition. He served on the Board of Directors for a few venture-backed healthcare companies, a few of which were focused on innovative hematology/oncology products. Prior to January 2007, he held commercial and leadership positions within Pfizer's oncology unit. He was a commercial leader within Pfizer's oncology unit, responsible for shepherding a portfolio of countless preclinical and clinical stage products through development using a fast-to-patient approach. Mr. Robbins served on the board of directors of Fate Therapeutics, Cytograft and StemCor Systems. Since October 2020, he has served as the Chief Executive Officer and President of Cognet Biosciences. Inc. Mr. Robbins holds an MBA from the Kellogg School of Management, Northwestern University and a Bachelor of Arts degree from Swarthmore College.

Positions